Periaswamy Velavan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Periaswamy Velavan has a total of 93 co-authors. Here are the top co-authors by number of shared publications:
- John George Franklin Cleland
School of Cardiovascular and Metabolic Health, University of Glasgow , Glasgow
10 shared publications Andrew L. Clark
5 shared publicationsAlison P. Coletta
Department of Cardiology, University of Hull, Castle Hill Hospital , Cottingham, Kingston-upon-Hull, HU15 5JQ
4 shared publicationsAlan S. Rigby
3 shared publications- Nick Freemantle
Institute of Clinical Trials and Methodology, University College London, London, UK
3 shared publications Afshin Khalatbari
Department of Cardiology, Liverpool Heart & Chest Hospital , Thomas Drive, Liverpool L14 3PE , UK
2 shared publications
Latest Publications
- Open Access
- 1 April 2023
- Published by Oxford University Press (OUP) in European Heart Journal - Case Reports
- Vol. 7 (4) , ytad165
Percutaneous left atrial appendage occlusion following successful treatment of large bi-atrial thrombi in a patient with atrial fibrillation: a case report
Background: Atrial fibrillation (AF) is a well-established risk factor for intracardiac thrombosis. Left atrial appendage occlusion (LAAO) is emerging as a viable alternative to oral anticoagulation (OAC) for high-risk AF patients who are contraindicated to long-term OAC. Case summary: A 74-year-old man with a history of permanent AF and subdural haemorrhage on warfarin therapy was referred to our facility for further management. Cardiac CT imaging revealed large bi-atrial thrombi for which apixaban therapy was initiated. Serial imaging over nine months showed gradual shrinkage and then resolution of the thrombi. In line with the patient’s preference to avoid life-long OAC, he received LAAO using an Amplatzer™ Amulet™ device. Follow-up transoesophageal echocardiography showed a well-seated device with no leak and no thrombus. Discussion: We discussed the key issues surrounding management of bi-atrial thrombi and the decision to perform LAAO in these circumstances, relying on shared decision making and multi-disciplinary team input.
- 1 April 2023
- Published by Oxford University Press (OUP) in European Heart Journal - Case Reports
- Vol. 7 (4) , ytad165
Open AccessPercutaneous left atrial appendage occlusion following successful treatment of large bi-atrial thrombi in a patient with atrial fibrillation: a case report
Background: Atrial fibrillation (AF) is a well-established risk factor for intracardiac thrombosis. Left atrial appendage occlusion (LAAO) is emerging as a viable alternative to oral anticoagulation (OAC) for high-risk AF patients who are contraindicated to long-term OAC. Case summary: A 74-year-old man with a history of permanent AF and subdural haemorrhage on warfarin therapy was referred to our facility for further management. Cardiac CT imaging revealed large bi-atrial thrombi for which apixaban therapy was initiated. Serial imaging over nine months showed gradual shrinkage and then resolution of the thrombi. In line with the patient’s preference to avoid life-long OAC, he received LAAO using an Amplatzer™ Amulet™ device. Follow-up transoesophageal echocardiography showed a well-seated device with no leak and no thrombus. Discussion: We discussed the key issues surrounding management of bi-atrial thrombi and the decision to perform LAAO in these circumstances, relying on shared decision making and multi-disciplinary team input.
- 26 February 2018
- Published by Oxford University Press (OUP) in European Heart Journal: Acute Cardiovascular Care
- Vol. 8 (5) , 421-431
A direct comparison of decision rules for early discharge of suspected acute coronary syndromes in the era of high sensitivity troponin
Background: We tested the hypothesis that a single high sensitivity troponin at limits of detection (LOD HSTnT) (99% certainty, allowing for early discharge of 53.4% and 36.9% respectively of suspected acute coronary syndrome. Adoption of either strategy has the potential to greatly reduce Emergency Room pressures and minimise follow-up investigations. Very early presenters (<3 h), due to limited numbers, are excluded from these conclusions.
- 26 February 2018
- Published by Oxford University Press (OUP) in European Heart Journal: Acute Cardiovascular Care
- Vol. 8 (5) , 421-431
A direct comparison of decision rules for early discharge of suspected acute coronary syndromes in the era of high sensitivity troponin
Background: We tested the hypothesis that a single high sensitivity troponin at limits of detection (LOD HSTnT) (99% certainty, allowing for early discharge of 53.4% and 36.9% respectively of suspected acute coronary syndrome. Adoption of either strategy has the potential to greatly reduce Emergency Room pressures and minimise follow-up investigations. Very early presenters (<3 h), due to limited numbers, are excluded from these conclusions.
Outcome of left atrial appendage occlusion in high-risk patients
Objective: Percutaneous left atrial appendage (LAA) occlusion can be an interventional alternative to oral anticoagulation for stroke prevention in patients with atrial fibrillation.Methods: We delivered LAA occlusion therapy using a standardised approach to patient referral, multidisciplinary team assessment, implant criteria, imaging and follow-up. We analysed patient characteristics, efficacy and safety of the implant procedure, and 12-month outcomes.Results: Of 143 referrals from October 2014 to December 2016, 83 patients (age 76±8years, 32.5% female, mean CHAD2S2-VASc score 4 ±1) were offered LAA occlusion. Eighty (95.3%) had previous major bleeding (intracranial in 59%). LAA occluder implantation with an Amulet device was successful in 82 (98.8%), with periprocedural major adverse events occurring in 5 (6.0%) patients (2 device embolisations including 1 death, 2 major bleeds). Cardiac imaging in 75 (94%) patients 2months following implant showed device-related thrombus in 1 case (1.3%) and minor (<5mm) device leaks in 13 (17.1%). Over a median 12-month follow-up, 3 (3.8%) ischaemic strokes, 2 (2.5%) haemorrhagic strokes and 5 (6.3%) major extracranial bleeds occurred. All-cause mortality was 10%, with most deaths (7, 87.5%) due to non-cardiovascular causes.Conclusions: LAA occlusion may be a reasonable option for stroke prevention inhigh-risk patients with atrial fibrillation ineligible for anticoagulation. However, procedural complication rates are not insignificant, and patients remain at risk of serious adverse events and death even after successful implant.
Outcome of left atrial appendage occlusion in high-risk patients
Objective: Percutaneous left atrial appendage (LAA) occlusion can be an interventional alternative to oral anticoagulation for stroke prevention in patients with atrial fibrillation.Methods: We delivered LAA occlusion therapy using a standardised approach to patient referral, multidisciplinary team assessment, implant criteria, imaging and follow-up. We analysed patient characteristics, efficacy and safety of the implant procedure, and 12-month outcomes.Results: Of 143 referrals from October 2014 to December 2016, 83 patients (age 76±8years, 32.5% female, mean CHAD2S2-VASc score 4 ±1) were offered LAA occlusion. Eighty (95.3%) had previous major bleeding (intracranial in 59%). LAA occluder implantation with an Amulet device was successful in 82 (98.8%), with periprocedural major adverse events occurring in 5 (6.0%) patients (2 device embolisations including 1 death, 2 major bleeds). Cardiac imaging in 75 (94%) patients 2months following implant showed device-related thrombus in 1 case (1.3%) and minor (<5mm) device leaks in 13 (17.1%). Over a median 12-month follow-up, 3 (3.8%) ischaemic strokes, 2 (2.5%) haemorrhagic strokes and 5 (6.3%) major extracranial bleeds occurred. All-cause mortality was 10%, with most deaths (7, 87.5%) due to non-cardiovascular causes.Conclusions: LAA occlusion may be a reasonable option for stroke prevention inhigh-risk patients with atrial fibrillation ineligible for anticoagulation. However, procedural complication rates are not insignificant, and patients remain at risk of serious adverse events and death even after successful implant.
- Top Cited Papers
- 1 November 2014
- Published by Elsevier in The Lancet
- Vol. 384 (9957) , 1849-1858
Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial
- 1 November 2014
- Published by Elsevier in The Lancet
- Vol. 384 (9957) , 1849-1858
Top Cited PapersUnfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial
- 1 February 2014
- Published by Elsevier in Journal of Cardiothoracic and Vascular Anesthesia
- Vol. 28 (1) , 110-111
First Report of the Use of Transesophageal Echocardiography to Position a Temporary Pacing Wire
- 1 February 2014
- Published by Elsevier in Journal of Cardiothoracic and Vascular Anesthesia
- Vol. 28 (1) , 110-111
First Report of the Use of Transesophageal Echocardiography to Position a Temporary Pacing Wire
- 1 February 2012
- Published by Europa Digital & Publishing in EuroIntervention
- Vol. 7 (10) , 1238-1244
How should I treat an entrapped rotational atherectomy burr?
The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)
- 1 February 2012
- Published by Europa Digital & Publishing in EuroIntervention
- Vol. 7 (10) , 1238-1244
How should I treat an entrapped rotational atherectomy burr?
The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)
- 1 February 2011
- Published by Europa Digital & Publishing in EuroIntervention
- Vol. 6 (7) , 895-899
How should I treat a spontaneously reperfused acute STEMI that involves the left main stem and proximal LAD?
The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)
- 1 February 2011
- Published by Europa Digital & Publishing in EuroIntervention
- Vol. 6 (7) , 895-899
How should I treat a spontaneously reperfused acute STEMI that involves the left main stem and proximal LAD?
The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)
- 1 January 2010
- Published by Elsevier in International Journal of Cardiology
- Vol. 138 (1) , 63-69
Predictors of short term mortality in heart failure — Insights from the Euro Heart Failure survey
- 1 January 2010
- Published by Elsevier in International Journal of Cardiology
- Vol. 138 (1) , 63-69
Predictors of short term mortality in heart failure — Insights from the Euro Heart Failure survey
- 1 February 2008
- Published by Oxford University Press (OUP) in Postgraduate Medical Journal
- Vol. 84 (988) , 99
Super conus-collateral
- 1 February 2008
- Published by Oxford University Press (OUP) in Postgraduate Medical Journal
- Vol. 84 (988) , 99
Super conus-collateral
- 1 January 2008
- Published by Wiley in Congestive Heart Failure
- Vol. 14 (1) , 55
Is the Controlled Rosuvastatin Multinational Study in Heart Failure (CORONA) the Answer to the Cholesterol Paradox in Heart Failure?
- 1 January 2008
- Published by Wiley in Congestive Heart Failure
- Vol. 14 (1) , 55
Is the Controlled Rosuvastatin Multinational Study in Heart Failure (CORONA) the Answer to the Cholesterol Paradox in Heart Failure?